|
Department of Pharmaceuticals to hire consultants to manage PRIP scheme
|
|
Our Bureau, New Delhi
May 06 , 2024
|
|
|
The Department of Pharmaceuticals (DoP) is planning to hire professionals as consultants to manage the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, announced last year to support research and development (R&D) and innovation in pharma, medical devices and animal health segments.
The Department has advertised requirements for two young professionals, a senior and a junior consultant, for the project management unit of the scheme on contract basis. The consultants are expected to support the DoP in administration, management and supervision of the scheme.
They also need to monitor and review the progress of selected projects under the scheme and appraise the progress of the scheme to the department.
The DoP has notified the Scheme PRIP with an outlay of Rs. 5,000 crore last August and has initiated efforts to identify the Project Management Agency (PMA) from Central public sector undertakings and public financial institutes. The proposed appointment of consultants is also part of these efforts to execute the scheme.
In terms of financial assistance from the total outlay of Rs. 5,000 crore, the establishment of CoEs in NIPERs will have an outlay of Rs. 700 crore, nine projects in the BI category will be eligible for R&D fund of around Rs. 1,125 crore, 30 projects in the BII will be eligible for Rs. 3,000 crore and 125 projects in BIII will have an outlay of Rs. 125 crore, over a period of five years. The total fund per year is estimated at Rs. 850 crore and the total administrative cost is estimated at Rs. 50 crore.
The scheme has two components comprising strengthening of research infrastructure through establishment of seven National Institutes of Pharmaceutical Education & Research (NIPERs) as Centres of Excellence (CoEs) in specific specialisations at a tentative cost of Rs. 700 crore and promotion of research in Pharma-MedTech sector by providing financial assistance for research in six priority areas - new chemical and biological entities, and natural products; complex generics and biosimilars; precision medicines; medical devices; orphan drugs; and drug development for antimicrobial resistance (AMR).
Under the second component of promotion of research in pharma and MedTech sector, the financial assistance will be provided in three categories. In the first category (BI), nine established pharma companies may be selected to carry out research in six priority areas with academic collaboration in government institute of national repute and these companies can avail the facilities of the research infrastructure available at national institutes, while these companies need to provide training to selected number of students and scientists of the institutes. In the second category (BII), in order to expedite the market launching and large-scale commercialisation process of products/technologies in priority areas having high commercial potential or societal impact financial assistance will be provided.
Under the third category (BIII), the funding would be provided to research projects in six priority areas to help Indian startups and Micro, Small and Medium Enterprises (MSMEs) to reach TRL 4. Under this category, DoP will provide financial support for projects in six priority areas which have clear potential to translate into commercial product/technology. Around 125 research projects from startups/SMEs/MSMEs having potential or having made sufficient headway in the research of priority areas will be selected and funding up to Rs. 1 crore per projects over a period of five years in milestone manner which would be provided from ideation to proof of concept on royalty sharing basis.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|